Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Seres Therapeutics, Inc.    MCRB

SERES THERAPEUTICS, INC.

(MCRB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seres Therapeutics, Inc. : Close to new upside potential

share with twitter share with LinkedIn share with facebook
share via e-mail
05/22/2020 | 12:06pm EDT
long trade
Target price hit
Entry price : 5.38$ | Target : 6.42$ | Stop-loss : 4.41$ | Potential : 19.33%
Seres Therapeutics, Inc. shares are trading close to a major technical resistance, which, if broken, could yield new upside potential and an increase in volatility. This scenario can be anticipated.
Investors have an opportunity to buy the stock and target the $ 6.42.
Seres Therapeutics, Inc. : Seres Therapeutics, Inc. : Close to new upside potential
Strengths
  • The group usually releases upbeat results with huge surprise rates.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The tendency within the weekly time frame is positive above the technical support level at 3.5 USD

Weaknesses
  • The stock is close to a major daily resistance at USD 5.43, which should be gotten rid of so as to gain new appreciation potential.
  • The company has insufficient levels of profitability.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

David Meurisse
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 35,8 M
EBIT 2020 -78,9 M
Net income 2020 -75,9 M
Finance 2020 51,4 M
Yield 2020 -
P/E ratio 2020 -6,55x
P/E ratio 2021 -6,03x
EV / Sales2020 11,1x
EV / Sales2021 7,62x
Capitalization 450 M
Upcoming event on SERES THERAPEUTICS, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 8,04 $
Last Close Price 6,20 $
Spread / Highest target 102%
Spread / Average Target 29,8%
Spread / Lowest Target -39,5%
EPS Revisions
Managers
NameTitle
Eric D. Shaff President, Chief Executive Officer & Director
Stephen A. Berenson Chairman
Marcus Chapman Chief Financial Officer & Senior Vice President
John G. Aunins CTO, Executive VP-Bioprocess & Manufacturing
Matthew R. Henn Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
SERES THERAPEUTICS, INC.60.29%401
GILEAD SCIENCES12.87%91 996
VERTEX PHARMACEUTICALS30.15%73 883
REGENERON PHARMACEUTICALS51.78%63 465
WUXI APPTEC CO., LTD.18.87%23 998
GENMAB A/S36.82%19 339